Beyond Celiac Investments backs Tolerance Bio in celiac disease push

Beyond Celiac Investments said June 22 it is investing in Tolerance Bio to advance a preclinical celiac disease program aimed at restoring immune tolerance through the thymus. The second BCI investment underscores growing venture-philanthropy support for therapies that could treat celiac disease at its root, not just manage symptoms.

Why it matters: - Beyond Celiac Investments is backing a strategy that aims to retrain the immune system in celiac disease, which could shift treatment away from symptom management. - The investment supports work that could move a novel therapeutic approach through early development and preclinical proof of concept. - The deal adds funding to one of the few autoimmune diseases with a known trigger, a point BCI says makes celiac a compelling target for new therapies.

What happened: - Beyond Celiac Investments, the venture philanthropy program of Beyond Celiac, announced an investment in Tolerance Bio Inc. on June 22, 2026. - The funding will support Tolerance Bio’s celiac disease program through early development and preclinical proof of concept. - This is BCI’s second investment as it builds a portfolio of preclinical and clinical-stage programs.

The details: - Tolerance Bio is developing therapies designed to preserve, restore and modulate thymic function. - The company’s approach targets the thymus, described as the body’s central regulator of immune function. - The goal is to re-establish immune tolerance and address celiac disease at its root. - BCI says its active diligence team is looking for opportunities that can accelerate meaningful treatments for celiac disease. - Beyond Celiac says it leads efforts to accelerate treatments and a cure for celiac disease. - More information is available in Beyond Celiac Investments. - Tolerance Bio says its broader pipeline includes monoclonal antibodies, cell therapies and mRNA approaches. - The company says its platform is focused on preserving, regenerating and modulating thymic function to address immune diseases and increase healthspan.

Between the lines: - The investment signals continued interest in celiac-focused biotech at an early stage, where scientific risk is high but differentiation can be strong. - BCI’s emphasis on discipline and science-based investing suggests the group is trying to build a concentrated portfolio rather than make broad bets. - The collaboration also links a patient-focused nonprofit investor with a company pursuing a potentially broader autoimmune platform.

What's next: - Tolerance Bio will use the funding to advance preclinical work and seek proof of concept for the celiac program. - BCI said it will keep evaluating additional preclinical and clinical-stage opportunities in celiac disease. - If the program advances, the company aims to move closer to the clinic with a fundamentally new treatment approach for autoimmune disease.

The bottom line: - BCI is deepening its bet on celiac disease, and Tolerance Bio is now one of the companies carrying that effort forward.